Tirbanibulin (Klisyri, Almirall) Improves AK Patients’ Satisfaction in Real-world Settings
Tirbanibulin (Klisyri, Almirall) performs as well in real-world practice as it does in clinical trials for actinic keratosis (AK), according to new analyses of Phase 3, Phase 4, and real-world studies presented at the 2025 American Academy of Dermatology’s Annual Meeting in Orlando, FL. Tirbanibulin is U.S. Food and Drug Administration-approved for the treatment of […]